ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Berberine inhibits the AcrB efflux pump and synergizes with meropenem against carbapenem-resistant hypervirulent Klebsiella pneumoniae: mechanistic insights and in vivo validation.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
From 285 non-duplicate clinical CRKP isolates, 170 were confirmed as carbapenem-resistant hypervirulent Klebsiella pneumoniae (CR-hvKP); after efflux pump phenotyping by the CCCP inhibition method and carbapenemase exclusion via Carba NP testing combined with multiplex carbapenemase gene PCR, 30 strains with AcrAB-TolC efflux-mediated resistance were selected for mechanistic investigation. Molecular docking revealed berberine binding to the AcrB Distal Binding Pocket (free energy: - 7.5 kcal/mol; hydrogen bond with SER-996, 2.6 Å). Checkerboard assays demonstrated synergistic berberine-meropenem activity against all 30 strains (fractional inhibitory concentration index, FICI: 0.1875-0.500; dimensionless). Nile red assays confirmed AcrB efflux inhibition comparable to PAβN, evidenced by attenuated intracellular fluorescence decay (ΔF/F₀ = - 9.7% vs. - 52.1% in AcrB-overexpressing controls). RT-qPCR showed berberine suppressed acrB transcription via upregulation of ramR and downregulation of ramA. Combination therapy significantly improved murine survival and bacterial clearance versus monotherapy (log-rank P < 0.001).
Indexed as
Identifiers
42714471What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.